Northern Capital Management LLC lifted its position in Allergan PLC. (NYSE:AGN) by 95.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,160 shares of the company’s stock after acquiring an additional 6,440 shares during the quarter. Allergan PLC. accounts for approximately 1.2% of Northern Capital Management LLC’s investment portfolio, making the stock its 28th largest holding. Northern Capital Management LLC’s holdings in Allergan PLC. were worth $3,199,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Honeywell International Inc. grew its stake in Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock valued at $40,871,000 after purchasing an additional 20,100 shares during the last quarter. Israel Discount Bank of New York purchased a new position in Allergan PLC. in the first quarter valued at about $988,000. Palladium Partners LLC grew its stake in Allergan PLC. by 1.7% in the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after purchasing an additional 523 shares during the last quarter. Trust Co. of Vermont grew its stake in Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after purchasing an additional 1,109 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Allergan PLC. in the second quarter valued at about $41,345,000. Institutional investors own 82.02% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) opened at 204.65 on Friday. The company has a 50-day moving average price of $229.79 and a 200-day moving average price of $236.07. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock has a market cap of $68.42 billion, a price-to-earnings ratio of 6.24 and a beta of 1.18.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $3.35 EPS. On average, analysts expect that Allergan PLC. will post $16.26 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.37%. Allergan PLC.’s dividend payout ratio is presently 9.95%.

COPYRIGHT VIOLATION NOTICE: “Northern Capital Management LLC Purchases 6,440 Shares of Allergan PLC. (AGN)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/23/northern-capital-management-llc-purchases-6440-shares-of-allergan-plc-agn.html.

AGN has been the topic of several analyst reports. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 6th. BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Wells Fargo & Company reiterated an “outperform” rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Credit Suisse Group set a $288.00 target price on Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, August 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $273.34.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.